FDA compounding status · updated 2026-08-03 · 119 compounds tracked
Is your peptide legal right now?
A plain-language status board for compounded peptides. Check any peptide's current FDA
compounding status, follow what the July advisory meeting decided, and verify a real licensed pharmacy. This is
information, not medical advice, and we don't sell peptides.
Most recent status event
PCAC advisory meeting · July 23-24, 2026
Meeting concluded
6
recommended so far
A committee recommendation is advisory. FDA has the final say, and until it acts nothing on this page becomes authorized to compound. See what the committee decided.
Vote record · PCAC July 23-24, 2026
What the FDA advisory committee decided
The advisory committee has finished its July 2026 review. Here is what it recommended for each peptide on the docket.
A recommendation is not permission. The Pharmacy Compounding Advisory Committee advises
FDA, it does not decide. FDA has not acted on these votes, so no peptide here has become legal
to compound, and nothing on this page has changed status because of them. Anyone selling on the
strength of this meeting is ahead of the agency, not in step with it.
About the vial images: every image is representative.
Cap colors organize topics; they do not identify a medicine, dose, pharmacy, or actual packaging.
PCAC voted to recommend for the 503A Bulks List, FDA decision pending
RecoveryPCAC voted 2026-07-23Status changed
PCAC 2026-07-23: the advisory committee voted to recommend adding this peptide to the 503A Bulks List by a vote of 8 for, 6 against, 1 abstention. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: BPC-157 is a synthetic peptide derived from a protein found in human gastric juice, studied in preclinical and limited human research in the context of tissue repair. Not FDA-approved for any use. Talk to a licensed clinician.
PCAC voted to recommend for the 503A Bulks List, FDA decision pending
RecoveryPCAC voted 2026-07-23Status changed
PCAC 2026-07-23: the advisory committee voted to recommend adding this peptide to the 503A Bulks List by a vote of 8 for, 6 against, 1 abstention. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: KPV is a naturally occurring tripeptide (Lys-Pro-Val), the C-terminal fragment of alpha-melanocyte-stimulating hormone, studied in animal and preclinical inflammation research related to the gut and skin. Not FDA-approved for any use. Talk to a licensed clinician.
PCAC voted to recommend for the 503A Bulks List, FDA decision pending
RecoveryPCAC voted 2026-07-23Status changed
PCAC 2026-07-23: the advisory committee voted to recommend adding this peptide to the 503A Bulks List by a vote of 8 for, 6 against, 1 abstention. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: TB-500 is a synthetic peptide corresponding to a fragment of thymosin beta-4, studied in animal and cell-based research in the context of tissue repair. Not FDA-approved for any use. Talk to a licensed clinician.
PCAC voted to recommend for the 503A Bulks List, FDA decision pending
MetabolicPCAC voted 2026-07-23Status changed
PCAC 2026-07-23: the advisory committee voted to recommend adding this peptide to the 503A Bulks List by a vote of 7 for, 5 against, 2 abstentions. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: MOTS-c is a naturally occurring, mitochondrial-derived peptide studied in preclinical and limited human research in the context of metabolic and exercise research, including glucose regulation. Not FDA-approved for any use. Talk to a licensed clinician.
PCAC voted against 503A Bulks List inclusion, FDA decision pending
CognitivePCAC voted 2026-07-24Status changed
PCAC 2026-07-24: the advisory committee voted against recommending this peptide for the 503A Bulks List by a vote of 6 for, 7 against, 1 abstention. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Emideltide (DSIP) is a naturally occurring nonapeptide, first isolated from rabbit blood, studied in animal and limited human research in the context of sleep and delta-wave EEG activity. Not FDA-approved for any use. Talk to a licensed clinician.
PCAC voted to recommend for the 503A Bulks List, FDA decision pending
CognitivePCAC voted 2026-07-24Status changed
PCAC 2026-07-24: the advisory committee voted to recommend adding this peptide to the 503A Bulks List by a vote of 8 for, 5 against, 1 abstention. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Semax is a synthetic heptapeptide derived from ACTH(4-7) with a Pro-Gly-Pro extension, studied in animal and limited human research in the context of neuroprotective research, including models of brain ischemia. Not FDA-approved for any use. Talk to a licensed clinician.
PCAC voted to recommend for the 503A Bulks List, FDA decision pending
LongevityPCAC voted 2026-07-24Status changed
PCAC 2026-07-24: the advisory committee voted to recommend adding this peptide to the 503A Bulks List by a vote of 7 for, 4 against, 1 abstention. This recommendation is not binding and FDA has not acted on it, so the status shown above has not changed.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on a pineal gland extract, studied in laboratory and animal research in the context of telomere biology and aging. Not FDA-approved for any use; talk to a licensed clinician.
Removed from Category 2 (Apr 2026), second PCAC review expected by Feb 2027
RecoveryReview 2027-02Status changed
Under re-verification: a source for this entry changed on 2026-08-03, we are re-checking it. (Frier Levitt peptide update)
What it is: LL-37 is a naturally occurring human peptide in the cathelicidin family, produced by skin and immune cells as part of innate immune defense, and studied in early-phase human research in the context of wound healing research. Not FDA-approved for any use; talk to a licensed clinician.
Removed from Category 2, second PCAC review pending
CognitiveReview 2027-02Status changed
Under re-verification: a source for this entry changed on 2026-08-03, we are re-checking it. (Frier Levitt peptide update)
What it is: Dihexa is a synthetic peptide derived from angiotensin IV that has been studied in animal and preclinical research in the context of cognitive function and memory. Not FDA-approved for any use. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-08-03, we are re-checking it. (Frier Levitt peptide update)
What it is: GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) studied in preclinical and limited human research in the context of skin regeneration and wound healing, and is not FDA-approved for any use, including injectable use. Talk to a licensed clinician.
Copper Peptide GHK-Cu, topical/non-injectable form
Category 1: under eval
Back on Category 1 (non-injectable routes); PCAC review pending
RecoveryReview 2027-02Status changed
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine copper complex) used in topical cosmetic formulations and studied in animal and limited human research in the context of skin structure and wound healing. It is not FDA-approved for any drug use. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-08-03, we are re-checking it. (Frier Levitt peptide update)
What it is: Melanotan II is a synthetic peptide analog of alpha-melanocyte-stimulating hormone studied in limited human research in the context of skin pigmentation. Not FDA-approved for any use; talk to a licensed clinician.
Removed from Category 2, second PCAC review pending
HormonalReview 2027-02Status changed
Under re-verification: a source for this entry changed on 2026-08-03, we are re-checking it. (Frier Levitt peptide update)
What it is: PEG-MGF is a synthetic, pegylated form of mechano growth factor (MGF), a splice variant of IGF-1, studied in preclinical and animal research in the context of satellite cell activation and tissue repair. Not FDA-approved for any use. Talk to a licensed clinician.
Not on 503A Bulks List; PCAC voted against inclusion Dec 2024
HormonalDisputedStatus changed
What it is: CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) studied in limited human research on growth hormone secretion and IGF-1 levels. Not FDA-approved for any use. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor agonist, studied in animal and limited human research in the context of growth hormone release. Not FDA-approved for any use. Talk to a licensed clinician.
Clearly compoundable (prior-approval pathway, not under PCAC review)
HormonalStatus changed
What it is: Sermorelin is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH) that was FDA-approved in 1997 under the brand name Geref for pediatric growth hormone deficiency, but the manufacturer discontinued that product in 2008 for commercial reasons and it is not currently FDA-approved as a marketed drug; compounded versions today are studied in the context of growth hormone secretion. Talk to a licensed clinician.
Withdrawn from Cat 2; PCAC rejected 503A listing, no review scheduled
LongevityStatus changed
What it is: Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide originally isolated from the thymus gland, studied in preclinical and limited human research in the context of immune system regulation and infectious disease research; it is not FDA-approved for any use in the United States. Talk to a licensed clinician.
Withdrawn from Cat 2; PCAC voted 0-12 against 503A listing (Dec 2024)
MetabolicStatus changed
What it is: AOD-9604 is a synthetic peptide fragment of human growth hormone studied in animal and limited human research in the context of fat metabolism and weight regulation. Not FDA-approved for any use. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-08-03, we are re-checking it. (Frier Levitt peptide update)
What it is: Selank is a synthetic peptide, an analog of the natural immune peptide tuftsin, studied in animal and limited human research in the context of anxiety research. Not FDA-approved for any use; talk to a licensed clinician.
FDA-approved drug (BLA) but reclassified biologic, not 503A/503B compounding-eligible
HormonalStatus changed
What it is: Tesamorelin is an FDA-approved growth hormone-releasing factor (GHRF) analog, marketed as Egrifta SV and Egrifta WR, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Talk to a licensed clinician.
What it is: PT-141 (bremelanotide), sold as Vyleesi, is an FDA-approved drug for hypoactive sexual desire disorder (HSDD) in premenopausal women, acting on melanocortin receptors tied to sexual desire regulation. Talk to a licensed clinician.
Not eligible for mass compounding; narrow 503A exception only
MetabolicStatus changed
What it is: Semaglutide is a synthetic peptide studied in extensive human clinical research in the context of appetite and blood sugar regulation. The compounded form offered by pharmacies is not FDA-approved for any use, so talk to a licensed clinician.
Not 503A/503B eligible outside narrow medical-necessity exceptions
MetabolicStatus changed
What it is: Tirzepatide is a peptide that is the active ingredient in the FDA-approved drugs Zepbound and Mounjaro, studied in extensive human clinical trials in the context of appetite and blood sugar. This compounded form is not itself FDA-approved and has not undergone FDA review for safety, effectiveness, or quality. Talk to a licensed clinician.
Not eligible for compounding (investigational drug)
MetabolicStatus changed
What it is: Retatrutide is a synthetic peptide and triple GLP-1/GIP/glucagon receptor agonist studied in Phase 3 human clinical trials in the context of body weight and blood sugar research. It is not FDA-approved for any use; talk to a licensed clinician.
Not FDA-approved, not on 503A/503B bulks list, warning-letter target
MetabolicStatus changed
What it is: 5-Amino-1MQ is a synthetic small molecule that inhibits the enzyme nicotinamide N-methyltransferase (NNMT), studied in animal and preclinical laboratory research in the context of metabolic regulation and adipose tissue biology. It is not FDA-approved for any use; talk to a licensed clinician.
FDA Category 1: bulk substance under evaluation (not Category 2)
RecoveryStatus changed
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Glutathione is a naturally occurring tripeptide antioxidant studied in laboratory and preclinical research in the context of oxidative stress and cellular protection. Compounded glutathione injections are not FDA-approved for any use; talk to a licensed clinician.
FDA Category 1: bulk substance under evaluation (not Category 2)
LongevityStatus changed
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: NAD+ is a naturally occurring coenzyme found in all living cells, studied in animal and limited human research in the context of cellular energy metabolism and aging. Not FDA-approved for any use. Talk to a licensed clinician.
Confirmed lawful dietary supplement (NDI), not a 503A compounding item
LongevityStatus changed
What it is: NMN (nicotinamide mononucleotide) is a naturally occurring nucleotide that functions as a precursor to NAD+, studied in preclinical and limited human research in the context of NAD+ metabolism and metabolic health. It is not FDA-approved for any use; talk to a licensed clinician.
What it is: Pinealon is a synthetic tripeptide (Glu-Asp-Arg) studied in animal and limited human research in the context of neuroprotection and cognitive aging, and it is not FDA-approved for any use. Talk to a licensed clinician.
FDA-approved drug (Forzinity), not 503A compounding eligible
LongevityStatus changed
What it is: Elamipretide, marketed as FORZINITY, is an FDA-approved drug indicated for muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, granted accelerated approval in September 2025. It is not approved for any other condition or population.
What it is: Thymulin is a naturally occurring zinc-dependent nonapeptide produced by thymic epithelial cells, studied in preclinical research in the context of T-cell differentiation and immune signaling. Not FDA-approved for any use; talk to a licensed clinician.
FDA-approved drug substance, freely compoundable component
LongevityStatus changed
What it is: Vitamin B12 (as cyanocobalamin or hydroxocobalamin) is the active ingredient in FDA-approved injectable drugs indicated for vitamin B12 deficiency, including pernicious anemia and malabsorption-related conditions, though compounded versions are not themselves separately FDA-approved products. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Kisspeptin-10 is a naturally occurring decapeptide studied in limited human and preclinical research in the context of reproductive hormone regulation. Not FDA-approved for any use. Talk to a licensed clinician.
Compoundable via USP/NF monograph pathway; confirmed absent from Category 2 and the July 2026 PCAC docket directly on FDA.gov
HormonalStatus changed
What it is: Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), the decapeptide the hypothalamus uses to signal the pituitary gland, previously FDA-approved as Factrel and Lutrepulse for diagnostic testing of pituitary-gonadal function though those approved products are discontinued and it is not FDA-approved for any use currently marketed in the United States. Talk to a licensed clinician.
What it is: HCG (human chorionic gonadotropin) is an FDA-approved injectable drug for ovulation induction in certain infertile women, hypogonadotropic hypogonadism in males, and evaluation of prepubertal cryptorchidism not due to anatomic obstruction. Talk to a licensed clinician for guidance on appropriate medical use.
FDA-approved active ingredient, compoundable under 503A
Sexual WellnessStatus changed
What it is: Oxytocin is a naturally occurring nine-amino-acid peptide hormone studied in limited human research in the context of social bonding and trust; compounded oxytocin (e.g. nasal spray) is not FDA-approved for any use. Talk to a licensed clinician.
What it is: Wolverine Blend combines two synthetic peptides, BPC-157 and TB-500, each studied in animal and limited preclinical research in the context of tissue repair and recovery. Neither peptide is FDA-approved for any use. Talk to a licensed clinician.
Status follows its components: GHK-Cu (injectable), BPC-157, TB-500
BlendsStatus changed
What it is: Glow Blend combines three peptides, GHK-Cu, BPC-157, and TB-500, studied in animal and preclinical laboratory research in the context of tissue repair and skin biology; none are FDA-approved for any use. Talk to a licensed clinician.
Status follows its components: BPC-157, TB-500, KPV, GHK-Cu (injectable)
BlendsStatus changed
What it is: Klow Blend is a combination of four peptides, BPC-157, TB-500, GHK-Cu, and KPV, studied in preclinical and animal research in the context of tissue repair and inflammation. Not FDA-approved for any use. Talk to a licensed clinician.
Status follows its components: Tesamorelin, Ipamorelin
BlendsStatus changed
What it is: Recompose Blend is a marketed name for a multi-peptide combination, typically pairing growth hormone-releasing peptides such as CJC-1295 and Ipamorelin, studied in limited human and preclinical body composition research involving fat and lean muscle mass. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: Focus Blend combines two synthetic peptides, Semax and Selank, individually studied in animal and limited human research in the context of cognitive function and stress response. Neither is FDA-approved for any use. Talk to a licensed clinician.
Status follows its components: Thymosin Alpha-1, Thymulin
BlendsStatus changed
What it is: Fortify Blend combines two naturally occurring thymic peptides, Thymosin Alpha-1 and Thymulin, each studied separately in preclinical and limited human research in the context of immune system regulation. Neither component is FDA-approved for any use as this combined product; talk to a licensed clinician before considering research compounds.
Not eligible for compounding (unapproved investigational drug)
MetabolicStatus changed
What it is: Amycretin is a synthetic peptide engineered to activate both GLP-1 and amylin receptors, studied in preclinical and early-phase human research in the context of appetite and blood sugar regulation. Not FDA-approved for any use. Talk to a licensed clinician.
FDA 503A Category 3 (nominated without adequate support); absent from July 2026 PCAC docket
RecoveryStatus changed
What it is: ARA-290 (cibinetide) is a synthetic 11-amino acid peptide derived from erythropoietin, studied in limited human clinical trials in the context of small fiber neuropathy and nerve regeneration research. Not FDA-approved for any use. Talk to a licensed clinician.
Acetyl Hexapeptide-8, SNAP-25 fragment mimetic, Acetyl Hexapeptide-3 (related)
Dietary supplement
Cosmetic ingredient, not FDA-regulated as a drug
DermatologicStatus changed
What it is: Argireline (Acetyl Hexapeptide-8) is a synthetic peptide fragment of the SNAP-25 protein, studied in cosmetic-formulation and in vitro research in the context of topical skin wrinkle appearance. Not FDA-approved for any use; talk to a licensed clinician.
Ala-Glu-Asp-Leu, AEDL, bronchial bioregulator, Bronchogen Bio
Unclassified
Not FDA-reviewed, no US regulatory footprint
LongevityStatus changed
What it is: Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide studied in preclinical and in vitro research in the context of bronchial tissue biology. Not FDA-approved for any use. Talk to a licensed clinician.
Cagrilintide acetate, CagriSema (combo with semaglutide)
Not 503A eligible
Not eligible for compounding (investigational, not FDA-approved)
MetabolicStatus changed
What it is: Cagrilintide is a synthetic long-acting amylin analog studied in human clinical trials in the context of appetite and body weight research, including in combination with the GLP-1 drug semaglutide. Not FDA-approved for any use. Talk to a licensed clinician.
Not eligible for compounding (unapproved investigational NDA product)
BlendsStatus changed
What it is: CagriSema Blend pairs cagrilintide, a synthetic amylin-receptor analog, with semaglutide, a GLP-1 receptor agonist, studied together in human clinical trials in the context of weight regulation research. Not FDA-approved for any use; talk to a licensed clinician.
Not FDA-approved; not eligible for 503A compounding
CognitiveStatus changed
What it is: Cerebrolysin is a porcine brain-derived peptide preparation studied in human clinical research in the context of cognitive recovery and neurological rehabilitation after conditions such as stroke and traumatic brain injury. It is not FDA-approved for any use in the United States; talk to a licensed clinician.
FDA-approved biologic (BLA); not eligible for compounding
MetabolicStatus changed
What it is: Dulaglutide (marketed as Trulicity) is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist injectable, indicated as an adjunct to diet and exercise for blood sugar control in adults and children 10 and older with type 2 diabetes, and for reducing major cardiovascular events in adults with type 2 diabetes. Talk to a licensed clinician.
503A Category 3 (no adequate support); 503B Category 2 for injectable/nasal routes
HormonalStatus changed
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: GHRP-2 (pralmorelin) is a synthetic peptide studied in limited human research on growth hormone secretion and appetite regulation. Not FDA-approved for any use in the United States. Talk to a licensed clinician.
Category 2, restricted, not on July 2026 PCAC agenda
HormonalStatus changed
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: GHRP-6 is a synthetic hexapeptide and ghrelin receptor agonist studied in animal and human research for its role in growth hormone secretion and appetite regulation. It is not FDA-approved for any use; talk to a licensed clinician.
Essentially-a-copy combo; capped at 4 scripts/month under 503A
BlendsStatus changed
What it is: GLP-1 receptor agonists are FDA-approved drugs for type 2 diabetes and weight management, but compounded blends that add vitamins or nutrients such as B12 are unapproved formulations whose safety and effectiveness as a combination have not been established. Talk to a licensed clinician.
Not on FDA 503A bulks list (any category); no PCAC review scheduled
HormonalStatus changed
What it is: Hexarelin is a synthetic peptide studied in animal and limited human research on growth hormone release and cardiovascular function. Not FDA-approved for any use. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: MK-677 (Ibutamoren) is a synthetic, non-peptide ghrelin receptor agonist studied in human clinical trials in the context of growth hormone and IGF-1 levels, appetite, and bone and muscle composition in older adults and people with growth hormone deficiency. It is not FDA-approved for any use; talk to a licensed clinician.
Status follows its components: Ipamorelin, CJC-1295
BlendsStatus changed
What it is: Ipamorelin and CJC-1295 are synthetic peptides studied together in preclinical and limited human research on growth hormone secretion from the pituitary gland. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Kisspeptin-54 is a naturally occurring 54-amino acid peptide encoded by the KISS1 gene that activates the GPR54 receptor, studied in human clinical research on the hypothalamic-pituitary-gonadal axis and reproductive endocrinology. Not FDA-approved for any use. Talk to a licensed clinician.
FDA-approved GLP-1 drug; 503B bulk-list exclusion proposed but not final
MetabolicStatus changed
What it is: Liraglutide is an FDA-approved GLP-1 receptor agonist, marketed as Victoza for blood sugar control in adults and children with type 2 diabetes and as Saxenda for chronic weight management, acting on pathways tied to appetite and blood sugar regulation. Talk to a licensed clinician to determine if it is appropriate for your situation.
Not eligible for compounding (unapproved investigational drug)
MetabolicStatus changed
What it is: Mazdutide is a synthetic peptide analogue of oxyntomodulin that activates both the GLP-1 and glucagon receptors, studied in human clinical trials in the context of weight management and blood sugar research. It is not FDA-approved for any use in the United States; talk to a licensed clinician.
FDA-approved drug (Scenesse implant); unapproved injectable version is a separate product
DermatologicStatus changed
What it is: Melanotan I is the original research name for afamelanotide, an FDA-approved drug (brand name Scenesse) indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). Talk to a licensed clinician for guidance specific to this drug.
Not FDA-approved; not 503A-eligible; FDA treats it as an unapproved new drug
CognitiveStatus changed
What it is: Noopept (also known as GVS-111 or omberacetam) is a synthetic dipeptide-derived compound studied in animal and limited human research in the context of cognitive function and memory research. It is not FDA-approved for any use in the United States and is not permitted for sale as a dietary supplement; talk to a licensed clinician.
What it is: P21 (P021) is a synthetic peptide derived from ciliary neurotrophic factor (CNTF), studied in animal research in the context of hippocampal neurogenesis and memory-related pathways in Alzheimer's disease models. Not FDA-approved for any use. Talk to a licensed clinician.
Investigational only, not FDA-approved, no 503A pathway
MetabolicStatus changed
What it is: Pemvidutide is a synthetic peptide, a dual GLP-1/glucagon receptor agonist, studied in human clinical trials in the context of appetite and blood sugar research, alongside liver fat and body weight research. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: PL-8177 is a synthetic melanocortin receptor 1 (MC1R) agonist peptide studied in preclinical and early-phase human research in the context of inflammatory bowel disease and ocular inflammation. It is not FDA-approved for any use; talk to a licensed clinician.
What it is: SNAP-8 (acetyl octapeptide-3) is a synthetic peptide studied in preclinical and in vitro neuromuscular signaling research related to skin and expression lines. Not FDA-approved for any use. Talk to a licensed clinician.
Not eligible for compounding (unapproved investigational drug)
MetabolicStatus changed
What it is: Survodutide is a synthetic peptide acting as a dual glucagon and GLP-1 receptor agonist, studied in preclinical and human clinical trials in the context of appetite and blood sugar research as well as liver fat research. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Thymosin Beta-4 (full-length) is a naturally occurring 43-amino-acid peptide studied in preclinical and limited human research in the context of tissue repair, including wound, corneal, and cardiac injury models; it is not FDA-approved for any use. Talk to a licensed clinician.
Under re-verification: a source for this entry changed on 2026-07-27, we are re-checking it. (FDA 503A bulk drug substances list (hub page))
What it is: Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino acid neuropeptide studied in preclinical and limited human research in the context of vasodilation, airway function, and immune regulation. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Vesugen (Lys-Glu-Asp) is a synthetic tripeptide studied in animal and preclinical research in the context of vascular tissue biology. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Vilon is a synthetic dipeptide (Lys-Glu) studied in animal and cell-culture research in the context of immune cell activity and inflammation. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: Abaloparatide (brand name Tymlos) is an FDA-approved synthetic peptide analog of parathyroid hormone-related protein, indicated for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture. Talk to a licensed clinician for guidance specific to your health status.
What it is: Calcitonin salmon is an FDA-approved drug for postmenopausal osteoporosis and Paget's disease of bone, given by injection or nasal spray. Talk to a licensed clinician for guidance on any therapy.
Not FDA-evaluated; oral supplement, outside 503A/PCAC scope
CognitiveStatus changed
What it is: Cerluten is a peptide complex derived from bovine cerebral cortex tissue that has been studied in limited, open-label human research in the context of central nervous system and cognitive function following conditions such as stroke or traumatic brain injury. It is not FDA-approved for any use; talk to a licensed clinician.
What it is: Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) studied in preclinical and animal research in the context of nerve cell and neural tissue differentiation. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: Cortexin is a naturally occurring peptide mixture derived from bovine or porcine cerebral cortex, studied in animal research in the context of neuroprotection and brain ischemia. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Crystagen (Glu-Asp-Pro) is a synthetic tripeptide studied in preclinical and limited elderly-human research in the context of immune cell function, and it is not FDA-approved for any use. Talk to a licensed clinician.
What it is: Dasiglucagon is an FDA-approved glucagon receptor agonist, marketed as Zegalogue, indicated for the treatment of severe hypoglycemia in people with diabetes aged 6 years and older. Talk to a licensed clinician.
What it is: Degarelix is an FDA-approved gonadotropin-releasing hormone (GnRH) receptor antagonist for advanced prostate cancer. Talk to a licensed clinician for guidance.
FDA-approved drug (not a compounding-list peptide)
HormonalStatus changed
What it is: Desmopressin is an FDA-approved synthetic peptide analog of the hormone vasopressin, indicated as antidiuretic replacement therapy for central diabetes insipidus and, in certain formulations, for managing bleeding episodes in hemophilia A and von Willebrand disease type I. Talk to a licensed clinician.
What it is: Eloralintide (LY3841136) is a synthetic amylin receptor agonist peptide studied in human clinical trials in the context of obesity and weight management research. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Endoluten is a peptide bioregulator complex derived from bovine pineal gland tissue, studied along with related pineal peptide preparations in preclinical and limited human research in the context of neuroendocrine regulation and aging. Not FDA-approved for any use. Talk to a licensed clinician.
FDA-approved drug (NDA), not a compounding bulk substance
MetabolicStatus changed
What it is: Exenatide is a GLP-1 receptor agonist and an FDA-approved medication indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
Not 503A eligible, treated as a biologic, absent from current 503A lists
RecoveryStatus changed
What it is: Follistatin is a naturally occurring protein that binds and neutralizes myostatin and activin, studied in preclinical and early-phase human research in the context of muscle growth regulation and muscular dystrophy; it is not FDA-approved for any use. Talk to a licensed clinician.
FDA-approved drug, not a compounding-review peptide
MetabolicStatus changed
What it is: Glucagon is an FDA-approved hormone drug indicated for severe hypoglycemia in adults and children with diabetes, and separately approved as a diagnostic aid to temporarily inhibit gastrointestinal movement during certain radiologic exams.
Not found on FDA's Category 1 or Category 2 compounding lists
RecoveryStatus changed
What it is: IGF-1 LR3 is a synthetic peptide analog of insulin-like growth factor 1, studied in preclinical animal and cell-culture research in the context of muscle growth signaling. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: Insulin aspart is an FDA-approved rapid-acting insulin analog indicated for glycemic control in adults and pediatric patients with type 1 and type 2 diabetes mellitus, marketed under brand names including NovoLog and Fiasp.
What it is: Insulin degludec, marketed as Tresiba, is an FDA-approved long-acting basal insulin analog indicated for glycemic control in patients with diabetes mellitus one year of age and older, first approved by the FDA in 2015. Its extended, flat time-action profile distinguishes it from rapid-acting insulin formulations. Talk to a licensed clinician.
What it is: Insulin detemir (brand name Levemir) is an FDA-approved long-acting insulin analog indicated for glycemic control in adults and children with diabetes mellitus. It is administered as a basal insulin alongside other diabetes medications and is not indicated for treatment of diabetic ketoacidosis.
What it is: Insulin glargine is a long-acting synthetic insulin analog that is an FDA-approved drug for glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Talk to a licensed clinician.
What it is: Insulin glulisine (brand name Apidra) is an FDA-approved rapid-acting insulin analog indicated for glycemic control in adults and children with type 1 or type 2 diabetes mellitus.
What it is: Insulin lispro is an FDA-approved rapid-acting insulin analog indicated for glycemic control in adults and children with diabetes mellitus. Talk to a licensed clinician.
What it is: Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu, INCI name Pentapeptide-18) related to natural enkephalins, studied in topical skin research in the context of neurotransmitter release and facial expression wrinkles. Not FDA-approved for any use. Talk to a licensed clinician.
FDA-approved drug, not a 503A bulk-compounding candidate
HormonalStatus changed
What it is: Leuprolide is an FDA-approved gonadotropin-releasing hormone (GnRH) agonist indicated for advanced prostate cancer, endometriosis, and central precocious puberty. Talk to a licensed clinician.
Dietary supplement, not a compounding-drug substance
Sexual WellnessStatus changed
What it is: Libidon is a peptide bioregulator complex isolated from animal prostate tissue, studied in preclinical and limited human research in the context of prostate gland function. Not FDA-approved for any use in the United States; talk to a licensed clinician.
What it is: Linaclotide is an FDA-approved drug, marketed as Linzess, for irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. Talk to a licensed clinician about whether it may be appropriate for you.
Adlyxin, Soliqua (combo with insulin glargine), Lyxumia
FDA approved
FDA-approved drug
MetabolicStatus changed
What it is: Lixisenatide, marketed as Adlyxin, is a synthetic peptide and an FDA-approved drug indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. Talk to a licensed clinician for personalized guidance.
What it is: Macimorelin (marketed as Macrilen) is an FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency, used as a diagnostic stimulation test rather than a treatment for any condition.
What it is: MariTide (maridebart cafraglutide) is a synthetic peptide-antibody conjugate studied in clinical trials in the context of appetite and blood sugar research. It is not FDA-approved for any use; talk to a licensed clinician.
Cosmetic-law ingredient, not a nominated drug substance
DermatologicStatus changed
What it is: Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a synthetic lipidated peptide studied in laboratory and topical human skin collagen research. Not FDA-approved as a drug for any use; talk to a licensed clinician.
Cosmetic-only peptides, no 503A compounding pathway
DermatologicStatus changed
What it is: Matrixyl 3000 is a proprietary complex of two synthetic peptides, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, marketed as a cosmetic ingredient and studied in laboratory and clinical research in the context of skin aging and collagen synthesis. It is not FDA-approved as a drug for any use; talk to a licensed clinician.
What it is: Mecasermin, sold under the brand name Increlex, is an FDA-approved drug for growth failure in pediatric patients with severe primary insulin-like growth factor-1 (IGF-1) deficiency or growth hormone gene deletion with neutralizing antibodies to GH. It is a recombinant, biosynthetic form of human IGF-1, the protein hormone at the center of ongoing growth and metabolism research. Talk to a licensed clinician for guidance specific to your situation.
What it is: N-Acetyl Selank Amidate is a synthetic peptide analog of Selank, studied in animal and preclinical research in the context of anxiety and stress. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: N-Acetyl Semax Amidate is a synthetic peptide analog of Semax, the ACTH(4-10) fragment, studied in animal and preclinical research in the context of cognitive research and neuroprotection. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Octreotide is an FDA-approved somatostatin analog indicated for acromegaly and for symptom control in metastatic carcinoid tumors and VIP-secreting tumors (VIPomas), per its DailyMed label. It is a synthetic octapeptide that mimics the natural hormone somatostatin and is marketed under brand names including Sandostatin.
What it is: Orforglipron (brand name Foundayo) is an FDA-approved, once-daily oral GLP-1 receptor agonist, a non-peptide small molecule, indicated for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition. Talk to a licensed clinician.
FDA-approved oral drug; other forms compoundable, not restricted
RecoveryStatus changed
What it is: Pentosan polysulfate sodium (brand name Elmiron) is an FDA-approved drug for the relief of bladder pain or discomfort associated with interstitial cystitis. Talk to a licensed clinician about appropriate use.
What it is: Petrelintide is a synthetic peptide analog of human amylin, studied in Phase 2 and Phase 3 human clinical trials in the context of appetite and body weight research. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: Plecanatide is an FDA-approved guanylate cyclase-C agonist peptide (brand name Trulance) indicated in adults for chronic idiopathic constipation and irritable bowel syndrome with constipation. Talk to a licensed clinician.
What it is: Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) studied in animal models and human cell-culture experiments in the context of prostate tissue and cellular aging research. It is not FDA-approved for any use; talk to a licensed clinician.
FDA-approved drug (NDA), not a compounding substance
MetabolicStatus changed
What it is: Setmelanotide (brand name Imcivree) is an FDA-approved melanocortin-4 receptor agonist for chronic weight management in adults and children with obesity linked to rare genetic conditions such as POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome. Talk to a licensed clinician.
What it is: Somatropin is a recombinant human growth hormone that is an FDA-approved prescription drug for growth hormone deficiency and related growth disorders such as Turner syndrome and Prader-Willi syndrome in children and adults. Talk to a licensed clinician.
What it is: Teriparatide (brand names Forteo and Bonsity) is an FDA-approved recombinant form of human parathyroid hormone (PTH 1-34), given by daily injection, indicated for postmenopausal women and men with osteoporosis at high risk of fracture, including glucocorticoid-induced osteoporosis. Talk to a licensed clinician.
What it is: Thymalin is a polypeptide complex extracted from calf thymus, studied in limited human clinical research in the context of immune regulation in older adults. Not FDA-approved for any use; talk to a licensed clinician.
What it is: Thymogen (Glu-Trp) is a synthetic dipeptide studied in laboratory and clinical research in Russia and Eastern Europe in the context of immune system regulation and T-cell activity. It is not FDA-approved for any use in the United States; talk to a licensed clinician.
What it is: Thymopentin is a synthetic pentapeptide corresponding to the active site of the natural thymic hormone thymopoietin, studied in limited human clinical research in the context of immune system modulation. Not FDA-approved for any use in the United States; talk to a licensed clinician.
What it is: Triptorelin is an FDA-approved gonadotropin-releasing hormone (GnRH) agonist, marketed as Trelstar for advanced prostate cancer and as Triptodur for central precocious puberty in patients 2 years and older. Talk to a licensed clinician for guidance specific to your situation.
What it is: Vasopressin is an FDA-approved injectable drug, sold under the brand name Vasostrict, indicated to raise blood pressure in adults with vasodilatory shock. It is also FDA-approved for diabetes insipidus caused by a deficiency of the body's natural antidiuretic hormone.
Sold as an oral dietary supplement, not a 503A compounding substance
RecoveryStatus changed
What it is: Ventfort is a peptide bioregulator complex derived from calf vascular (aorta) tissue, studied in preclinical and limited human research in the context of vascular wall biology and blood vessel aging. Not FDA-approved for any use. Talk to a licensed clinician.
What it is: Vladonix is a peptide bioregulator complex derived from calf thymus tissue, studied in limited human research in the context of immune regulation after radiation and chemotherapy exposure. Not FDA-approved for any use; talk to a licensed clinician.
No peptides match.Try a different name, or clear the filters.
Before you spend a dollar
Real source, or a legal dodge?
The cheapest option is usually the most dangerous one. A "research use only" vial isn't a
bargain. It's unregulated and unverified. Here's how to tell the difference, and what a fair price
actually looks like.
The 4-point check
1
Licensed pharmacy, not a "research chemical" vendor
Vials labeled "not for human consumption" are a legal dodge. Real sources are state-licensed 503A/503B pharmacies that dispense on a prescription.
2
A prescriber is actually involved
Legit peptides come through a licensed clinician who evaluates you. No prescription and no medical oversight is a red flag.
3
They can show credentials
State licensing, NABP/PCAB or LegitScript, and a third-party certificate of analysis with a lot number. Vague origin, no address, walk away.
4
The compound is actually compoundable
Some peptides are restricted or not FDA-eligible. Check its status on the board above first.
What a fair price looks like
Gray-market "research" vialsNo oversight, no sterility guarantee, no standardized dose
$30-100 · avoid
Telehealth clinicsConvenience plus a remote prescriber. Verify the pharmacy behind it
$150-425 /mo
In-person clinicsFull evaluation and monitoring
$400-1,300 /cycle
Ranges are general market observations for orientation, not quotes. Actual price depends
on the compound, dose, pharmacy, and your prescriber.
Talk to a licensed clinician before choosing a source or spending money on any peptide.
How we got here
The regulatory timeline
Why the status keeps moving. This is the sequence that put peptides in a do-not-compound
bucket, then started pulling some back out.
2023-09
FDA established the interim Category 2 grouping placing 19 peptides in the do-not-compound bucket.
2026-02-27
HHS Secretary R.F. Kennedy Jr. publicly signaled ~14 of 19 Category 2 peptides would move back toward Category 1.
2026-04-15
FDA published removal of 12 peptides from Category 2. Removal is NOT authorization to compound.
2026-04-16
Federal Register notice of the PCAC meeting published (distinct document from the Apr 15 removal notice).
2026-05-14
FDA reported to have restored non-injectable GHK-Cu to Category 1 on the 503A bulk drug substances list.
2026-06-30
Deadline to request to make an oral presentation at the July PCAC meeting.
2026-07-09
Written comment submission deadline for the July PCAC meeting.
2026-07-23
PCAC meeting Day 1 (FDA White Oak, Silver Spring MD). Reviews BPC-157, KPV, TB-500, MOTs-C for the 503A bulk substances list.
2026-07-24
PCAC meeting Day 2. Reviews Emideltide (DSIP), Semax, Epitalon.
2027-02
Second PCAC meeting expected before end of Feb 2027 for the remaining 5: LL-37, Dihexa, GHK-Cu (injectable), Melanotan II, PEG-MGF.
Why the gray market is a real risk, not a scare tactic
Recent FDA enforcement
Straight from the FDA's own public record.
2026-03-03
FDA warned 30 telehealth companies over illegal compounded GLP-1 marketing. FDA cited misleading claims, including implying compounded semaglutide has the 'same active ingredient' as approved brand drugs. FDA source
2026-03-31
FDA sent warning letters to 7 research-peptide sellers. Named sellers marketed peptides as 'Research Use Only.' FDA rejected that label as a defense, stating website evidence showed the products were intended as drugs. FDA source
2025-09-22
FDA warning letter to Revive Rx Pharmacy. The pharmacy produced HCG and Thymosin Beta-4 as biological products that are not eligible for 503A/503B compounding exemptions. FDA source
2025-05
FDA ended shortage-based compounding discretion for semaglutide and tirzepatide. With the national GLP-1 shortage resolved, compounding copies of the brand drugs is no longer covered by FDA's earlier enforcement discretion absent a documented individual medical need. FDA source
Public-record information · not an endorsement
Licensed compounding pharmacies
State-licensed 503A and 503B pharmacies with publicly verifiable credentials, for your own
research. We don't take a cut of any sale. Here is how to verify any pharmacy yourself.
We exclude pharmacies with recent FDA enforcement actions (currently: Revive Rx Pharmacy).
Strive Compounding Pharmacy
St. Louis, MO
503A
Telehealth-focused; nationwide direct-to-patient shipping. Publishes QA claims (weekly potency testing). Accreditation list is from the pharmacy's own site; confirm each is current. Licensed in all 50 states.
Belmar Pharma Solutions operates 503A + 503B facilities; acquired APS Pharmacy (2020). Alliance for Pharmacy Compounding member (per secondary sources). No individual compound was confirmed by name on this pass, so no per-peptide match is claimed. Verify accreditations directly. Multi-state (CO + FL facilities).
Prescription required from a licensed clinician.
NABPoffers peptidesprovider portalcreds pending
Olympia Pharmacy
Orlando, FL
503A503B
Affiliated 503A pharmacy + 503B outsourcing facility. Confirm which entity holds which registration. Ships nationwide.
Family-run 503A pharmacy operating since 2007 (traces lineage to two older local pharmacies). Says it is Sarasota County's only PCCA-accredited compounding pharmacy; no PCAB/NABP/ACHC/LegitScript claim found on this pass. No state license number or nationwide-shipping claim confirmed, verify directly. Florida-based (confirm coverage before assuming nationwide shipping).
Prescription required from a licensed clinician.
PCCA memberoffers peptidescreds pending
Hallandale Pharmacy
Hallandale Beach, FL
503A
503A compounding pharmacy; provider portal via LifeFile e-prescribing. Site nav includes a Peptide Therapy category but no individual compound was confirmed by name on this pass, so no per-peptide match is claimed. Specific accreditations not captured this pass, verify before listing them. Multi-state (confirm coverage).
Prescription required from a licensed clinician.
offers peptidesprovider portalcreds pending
Tailor Made Compounding
Nicholasville, KY
503A
Peptide-focused 503A; heavy practitioner education. Acquired by Noom (2026). No individual compound was confirmed by name on this pass, so no per-peptide match is claimed. Confirm state coverage + accreditations. Reported ~46 states.
Prescription required from a licensed clinician.
offers peptidesprovider portalcreds pending
From real Reddit threads, Google searches, and forums
Common questions
30 questions answered with sources, plus a doctor-routed answer for the
ones that need a clinician, not a website.
